Sugi Predict

Sugi Predict / Compounds / SCHEMBL145680

SCHEMBL145680

SCHEMBL145680

CC1=C[C@@]2(C)[C@@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]32)CC1=O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 4/20 0.57
▸ SHBG P04278 3/20 0.57
▸ GPBAR1 Q8TDU6 3/20 0.57
▸ AR P10275 2/20 0.57
▸ SERPINA6 P08185 2/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ NR3C1 P04150 1/20 0.57
▸ PGR P06401 1/20 0.57
▸ NR3C2 P08235 1/20 0.57
▸ MGAM O43451 1/20 0.57
▸ PRKCA P17252 1/20 0.51
▸ LMNA P02545 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ MBOAT4 Q96T53 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4936801 1.00 CYP19A1 (0.57) CYP19A1SHBGGPBAR1ARSERPINA6
SCHEMBL11332329 1.00 CYP19A1 (0.57) CYP19A1SHBGGPBAR1ARSERPINA6
Acetic Acid SCHEMBL636808 0.95 CYP19A1 (0.53) CYP19A1SHBGGPBAR1ARSERPINA6
SCHEMBL10891187 0.87 CYP19A1 (0.56) CYP19A1SHBGGPBAR1ARSERPINA6
SCHEMBL10891182 0.87 CYP19A1 (0.56) CYP19A1SHBGGPBAR1ARSERPINA6
Acetic Acid Pentyl Ester SCHEMBL27748017 0.86 CYP19A1 (0.44) CYP19A1SHBGGPBAR1ARSERPINA6
SCHEMBL11324212 0.83 MBOAT4 (0.46) CYP19A1SHBGGPBAR1ARSERPINA6
SCHEMBL11324207 0.83 MBOAT4 (0.46) CYP19A1SHBGGPBAR1ARSERPINA6
SCHEMBL7082952 0.82 MBOAT4 (0.45) CYP19A1SHBGGPBAR1ARSERPINA6
SCHEMBL7082956 0.82 MBOAT4 (0.45) CYP19A1SHBGGPBAR1ARSERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3612223-B1 TREATING MALE SENESCENCE NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2024-07-31 — — EP claimed
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 — — US claimed
US-10940151-B2 Methods for treating renal disease BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2021-03-09 — — US claimed
EP-3612223-A1 Treating Male Senescence National Institute Of Biological Sciences, Beijing (CN) 2020-02-26 — — EP claimed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 — — US claimed
US-20190117659-A1 METHODS FOR TREATING RENAL DISEASE BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2019-04-25 — — US claimed
US-10130632-B2 Methods for treating renal disease BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2018-11-20 — — US claimed
WO-2018192416-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-10-25 — — WO claimed
US-20180169069-A1 COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA VICUS THERAPEUTICS LLC (US) 2018-06-21 — — US claimed
US-9770514-B2 Tamper-resistant pharmaceutical dosage forms ExxPharma Therapeutics LLC (US) 2017-09-26 — — US claimed
CN-1543349-A Enhanced drug delivery in transdermal systems ŵ��ҩƷ��˾ 2004-11-03 — — CN claimed
EP-1406633-A1 ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS NOVEN PHARMACEUTICALS, INC. (US) 2004-04-14 — — EP claimed
US-20030232073-A1 Enhanced drug delivery in transdermal systems NOVEN PHARMACEUTICALS, INC. 2003-12-18 — — US claimed
US-20030152614-A1 Enhanced drug delivery in transdermal systems NOVEN PHARMACEUTICALS, INC. 2003-08-14 — — US claimed
US-20030152615-A1 Enhanced drug delivery in transdermal systems NOVEN PHARMACEUTICALS, INC. 2003-08-14 — — US claimed
US-20030152613-A1 Enhanced drug delivery in transdermal systems NOVEN PHARMACEUTICALS, INC. 2003-08-14 — — US claimed
WO-2002102390-A1 ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS NOVEN PHARMACEUTICALS, INC. (US) 2002-12-27 — — WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
EP-0496520-A1 Novel bone acting agents MERCK & CO. INC. (US) 1992-07-29 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117659-A1 METHODS FOR TREATING RENAL DISEASE LDLR, APOL1, APOB CYP19A1 4609/4885SHBG 2277/4885GPBAR1 673/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL CYP19A1 669/4885SHBG 293/4885GPBAR1 3678/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL CYP19A1 669/4885SHBG 293/4885GPBAR1 3678/4885
US-10130632-B2 Methods for treating renal disease LDLR, APOL1, APOB CYP19A1 4609/4885SHBG 2277/4885GPBAR1 673/4885
US-10940151-B2 Methods for treating renal disease LDLR, APOL1, APOB CYP19A1 4609/4885SHBG 2277/4885GPBAR1 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.